Published • loading... • Updated
Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation
- On May 22, 2025, Phraxis Inc., a medical device company headquartered in Minneapolis, received FDA approval for its EndoForce Connector designed for endovascular venous anastomosis.
- The approval follows a pivotal, multicenter, single-arm study that demonstrated EndoForce's ability to simplify arteriovenous graft creation while addressing vascular access challenges.
- EndoForce is a patented implant designed to enable precise vessel-to-graft alignment without surgical venous dissection, aiming to reduce tissue trauma and improve procedural workflow.
- The study achieved a 92% cumulative patency rate at six months and confirmed technical and primary patency success, with John Ross, MD, highlighting its novel, straightforward approach.
- Phraxis has made EndoForce available to clinicians, signaling a potential advancement in durable dialysis access solutions for patients with end-stage renal disease.
Insights by Ground AI
19 Articles
19 Articles
onidawatchman.com+18 Reposted by 18 other sources
Phraxis Announces FDA Approval of EndoForce™ Connector for Endovascular Venous Anastomosis, Advancing Dialysis Access Innovation
MINNEAPOLIS, May 22, 2025 /PRNewswire/ -- Phraxis Inc., a Minneapolis-based medical device company, marks a major milestone with FDA approval of the EndoForce™ Connector for Endovascular Venous Anastomosis (EndoForce™) — a pivotal development in the evolution of dialysis access technology.
·Onida, United States
Read Full ArticleCoverage Details
Total News Sources19
Leaning Left0Leaning Right0Center16Last UpdatedBias Distribution100% Center
Bias Distribution
- 100% of the sources are Center
100% Center
C 100%
Factuality
To view factuality data please Upgrade to Premium
